GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (NAS:ASND) » Definitions » Price-to-Owner-Earnings

ASND (Ascendis Pharma AS) Price-to-Owner-Earnings : (As of Apr. 13, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Ascendis Pharma AS Price-to-Owner-Earnings?

As of today (2025-04-13), Ascendis Pharma AS's share price is $150.99. Ascendis Pharma AS does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Ascendis Pharma AS's Price-to-Owner-Earnings or its related term are showing as below:


ASND's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 30.005
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-04-13), Ascendis Pharma AS's share price is $150.99. Ascendis Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-7.14. Therefore, Ascendis Pharma AS's PE Ratio (TTM) for today is At Loss.

As of today (2025-04-13), Ascendis Pharma AS's share price is $150.99. Ascendis Pharma AS's EPS without NRI for the trailing twelve months (TTM) ended in was $-7.14. Therefore, Ascendis Pharma AS's PE Ratio without NRI for today is At Loss.


Ascendis Pharma AS Price-to-Owner-Earnings Historical Data

The historical data trend for Ascendis Pharma AS's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma AS Price-to-Owner-Earnings Chart

Ascendis Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ascendis Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ascendis Pharma AS's Price-to-Owner-Earnings

For the Biotechnology subindustry, Ascendis Pharma AS's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Price-to-Owner-Earnings falls into.


;
;

Ascendis Pharma AS Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Ascendis Pharma AS's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=150.99/-8.58
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascendis Pharma AS  (NAS:ASND) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Ascendis Pharma AS Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma AS's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma AS Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.